GLP-1 RAs in Steatotic Liver Disease (MASLD, MetALD, and ALD) Although not yet specifically approved for the treatment of MASLD, GLP-1 RAs exhibit pleiotropic effects that contribute to the improvement of MASLD and its progression to metabolic dysfunction-associated steatohepatitis (MASH) (Table 3)
But allow 2-4 weeks between peptides to assess individual responses and avoid overlapping effects
[2] The other adverse effects are limited to nausea, vomiting, diarrhea, abdominal pain, constipation, and a small percentage of cases of hypoglycemia (a blood sugar lower than 70 mg/dL) which can be lethal but has not been the case, so far, with Ozempic
I am a prof
However, because the intestines contain an enzyme that degrades glutathione, this can reduce the bioavailability of glutathione in food and also most oral supplements